Frank Lovecchio, DO
Internal Medicine · Phoenix, AZNPI 1881663896
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $728,046 of the $910,698 with a category attached, or 79.9%. AbbVie accounts for 81.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $190,445 and has fallen 68.8% since, to $59,445 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,567 payments — averaging $581.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$745K
- Genentech USA, Inc.$50K
- AstraZeneca$48K
- Bioxcel Therapeutics, Inc.$22K
- Paratek Pharmaceuticals, Inc.$15K
- Otsuka America Pharmaceutical, Inc.$10K
- plus $22K from 12 others
Across 11 payments — averaging $3094.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$15K
- AstraZeneca$10K
- Seqirus USA Inc$9K
What the payments were for
- Consulting fees$43,0285%
- Speaking & faculty fees$728,04680%
- Travel & lodging$116,24113%
- Food & beverage$23,3833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,330 | $744,925 |
| Genentech USA, Inc. | 46 | $49,547 |
| AstraZeneca(2 entities) | 70 | $47,646 |
| Bioxcel Therapeutics, Inc. | 51 | $21,666 |
| Paratek Pharmaceuticals, Inc. | 22 | $15,064 |
| Otsuka America Pharmaceutical, Inc. | 17 | $10,069 |
| Genentech, Inc. | 8 | $6,956 |
| Johnson & Johnson | 7 | $6,573 |
| Melinta Therapeutics, LLC | 4 | $3,308 |
| Sanofi Pasteur Inc. | 2 | $2,283 |
| GSK | 1 | $1,950 |
| Viiv Healthcare Company | 3 | $237 |
| Alphatec Spine, Inc | 1 | $195 |
| Globus Medical | 1 | $190 |
| Gilead | 1 | $27 |
| Nevro Corp. | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$910,698 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Phoenix
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Mark WongPhoenix$71K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
- Louise TaberPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.